[1]安丽,王秋月.Visfatin与胰岛素抵抗及糖尿病肾病的发病机制[J].国际内分泌代谢杂志,2015,(04):248-251.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]
　An Li,Wang Qiuyue..Visfatin in the pathogenesis of insulin resistance and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):248-251.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]
点击复制

Visfatin与胰岛素抵抗及糖尿病肾病的发病机制()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2015年04
页码:
248-251
栏目:
糖尿病肾病专栏
出版日期:
2015-07-20

文章信息/Info

Title:
Visfatin in the pathogenesis of insulin resistance and diabetic nephropathy
作者:
安丽; 王秋月
110001　沈阳，中国医科大学附属第一医院内分泌与代谢病科
Author(s):
An Li; Wang Qiuyue.
Department of Endocrinology and Metabolism，The First Affiliated Hospital，China Medical University，Shenyang 110001，China Corresponding author：Wang Qiuyue，Email：wqycmu@163.com
关键词:
Visfatin; 糖尿病肾病; 胰岛素抵抗
Keywords:
Visfatin; Diabetic nephropathy; Insulin resistance
DOI:
10.3760/cma.j.issn.1673-4157.2015.04.009
摘要:
Visfatin是哺乳动物合成烟酰胺腺嘌呤二核苷酸（NAD）的限速酶，同时具有类炎性反应因子样作用，可通过cAMP反应元件结合蛋白/蛋白激酶A途径调控肝脏糖异生及葡萄糖代谢，通过NAD、沉默信息调节因子1参与调节胰岛素敏感性及胰岛β细胞功能。此外，visfatin还可调节肾细胞的胰岛素信号转导及葡萄糖代谢，与炎性因子、肾素-血管紧张素系统相互作用，参与糖尿病肾病的发生、发展，为糖尿病及糖尿病肾病的治疗提供新思路。
Abstract:
Visfatin is the rate-limiting enzyme in the synthesis of nicotinamide adenine dinucleotide(NAD) in mammalian cell，and it also has effects of simulating inflammatory cytokines. Visfatin is involved in the control of liver gluconeogenesis and glucose metabolism through cAMP-responsive element binding protein/protein kinase A pathway. Moreover，visfatin regulates insulin sensitivity and islet beta cell function by modulation NAD and silent information regulator 1. In addition，visfatin is involved in the regulation of insulin signal transduction and glucose metabolism of renal cells.It may also play roles in diabetic nephropathy by interacting with inflammatory factors and renin-angiotensin system，which shed light on the therapy of diabetes and diabetic nephropathy.

参考文献/References:

[1]　Kukla M，Mazur W，Bu?覥dak RJ，et al.Potential role of leptin， adiponectin and three novel adipokines-visfatin，chemerin and vaspin-in chronic hepatitis[J].Mol Med，2011，17（11-12）：1397-1410. 　
[2]　Revollo JR，K?觟rner A，Mills KF，et al.Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme[J].Cell Metab，2007，6（5）：363-375. 　
[3]　Imai S，Yoshino J.The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing[J].Diabetes Obes Metab，2013，15（Suppl 3）：26-33. 　
[4]　Lee JH，Song MY，Song EK，et al.Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway[J].Diabetes，2009，58（2）：344-351. 　
[5]　Wang RH，Kim HS，Xiao C，et al.Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia，oxidative damage，and insulin resistance[J].J Clin Invest，2011， 121（11）：4477-4490. 　
[6]　Ramsey KM，Mills KF，Satoh A，et al.Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing （BESTO） mice[J].Aging Cell，2008，7（1）：78-88. 　
[7]　Spinnler R，Gorski T，Stolz K，et al.The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion[J].PLoS One，2013，8（1）：e54106. 　
[8]　Caton PW，Kieswich J，Yaqoob MM，et al.Nicotinamide mononu-cleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function[J].Diabetologia，2011，54（12）：3083-3092. 　
[9]　Chang YH，Chang DM，Lin KC，et al.Visfatin in overweight/obesity，type 2 diabetes mellitus，insulin resistance，metabolic syndrome and cardiovascular diseases：a meta-analysis and systemic review[J].Diabetes Metab Res Rev，2011，27（6）：515-527.
[10]　Goktas Z，Owens S，Boylan M，et al.Associations between tissue visfatin/nicotinamide，phosphoribosyltransferase（Nampt），retinol binding protein-4，and vaspin concentrations and insulin resis-tance in morbidly obese subjects[J].Mediators Inflamm，2013， 2013：861496.
[11]　Nourbakhsh M，Nourbakhsh M，Gholinejad Z，et al.Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome[J].Scand J Clin Lab Invest，2015，75（2）：183-188.
[12]　Gouranton E，Romier B，Marcotorchino J，et al.Visfatin is involved in TNF?琢-mediated insulin resistance via an NAD（+）/Sirt1/PTP1B pathway in 3T3-L1 adipocytes[J].Adipocyte，2014，3（3）：180-189.
[13]　Sun C，Zhang F，Ge X，et al.SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B[J].Cell Metab，2007，6（4）：307-319.
[14]　Choi YJ，Choi SE，Ha ES，et al.Extracellular visfatin activates gluconeogenesis in HepG2 cells through the classical PKA/CREB-dependent pathway[J].Horm Metab Res，2014，46（4）：233-239.
[15]　Song HK，Lee MH，Kim BK，et al.Visfatin：a new player in mesangial cell physiology and diabetic nephropathy[J].AM J Physiol Renal Physiol，2008，295（5）：F1485-F1494.
[16]　Kang YS，Song HK，Lee MH，et al.Visfatin is upregulated in type-2 diabetic rats and targets renal cells[J].Kidney Int，2010， 78（2）：170-181.
[17]　Bessa SS，Hamdy SM，El-Sheikh RG.Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease：an Egyptian study[J].Eur J Intern Med，2010，21（6）：530-535.
[18]　Benito-Martin A，Ucero AC，Izquierdo MC，et al.Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells[J].Biochim Biophys Acta，2014，1842（2）：293-303.
[19]　Kang YS，Song HK，Lee MH，et al.Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients[J].Diabetes Res Clin Pract，2010，89（2）：141-149.
[20]　Takase O，Marumo T，Imai N，et al.NF-kappaB-dependent increase in intrarenal angiotensin Ⅱ induced by proteinuria[J].Kindey Int，2005，68（2）：464-473.
[21]　Huang Q，Guo Y，Zeng H，et al.Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells[J].Endocr Res，2011，36（3）：93-100.
[22]　Eyileten T，Sonmez A，Saglam M，et al.Effect of renin-angiotensin aldosterone system （RAAS） blockade on visfatin levels in diabetic nephropathy[J].Nephrology（Carlton），2010，15（2）：225-229.

相似文献/References:

[1].2007年糖尿病新进展学习班将举办[J].国际内分泌代谢杂志,2007,(04):226.
[2]李英,段惠军.Raf/MEK/ERK信号转导通路在糖尿病肾病发生发展中的作用[J].国际内分泌代谢杂志,2007,(04):264.
[3]张红 章向成 朱大龙.炎性反应与糖尿病肾病[J].国际内分泌代谢杂志,2015,(01):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
　Zhang Hong*,Zhang Xiangcheng,Zhu Dalong..Role of inflammation in diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
[4]邵滢,王秋月.Mir-217/Sirt1通路与糖尿病肾病[J].国际内分泌代谢杂志,2015,(02):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
　Shao Ying,Wang Qiuyue..Mir-217 / Sirt1 pathway and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
[5]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
　Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[6]任慧雯,王秋月.Epac-Rap1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
　Ren Huiwen,Wang Qiuyue..Epac-Rap1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
[7]邵滢,王秋月.MiRNA-150与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
　Shao Ying,Wang Qiuyue..MiRNA-150 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
[8]陈堃,刘超,陈国芳,等.糖尿病肾病诊断标志物研究进展[J].国际内分泌代谢杂志,2015,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
　Chen Kun,Liu Chao,Chen Guofang,et al.Urinary biomarkers for diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
[9]任慧雯,王秋月.Vasohibin-1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(04):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
　Ren Huiwen,Wang Qiuyue..Vasohibin-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
[10]任惠珠,王珊珊,郑妙艳,等.肾小球基底膜中胶原的合成、降解与糖尿病肾病[J].国际内分泌代谢杂志,2015,(04):252.[doi:10.3760/cma.j.issn.1673-4157.2015.04.010]
　Ren Huizhu,Wang Shanshan,Zheng Miaoyan,et al.Synthesis and degradation of collagen in glomerular basement membrane and their associations with diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):252.[doi:10.3760/cma.j.issn.1673-4157.2015.04.010]

备注/Memo

备注/Memo:
基金项目：辽宁省特聘教授科研基金（2015年）；辽宁省科技攻关计划项目（2011225017）；沈阳市科技攻关计划项目（F11-262-9-06） 　　通信作者：王秋月，Email：wqycmu@163.com
更新日期/Last Update: 2015-07-20